FX Shoulder Prospective Clinical Study

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorFX Shoulder Solutions

About this trial

Prospective Multi-Center Registry on study subjects with implanted devices marketed and legally commercialized in the USA by FX Shoulder Solutions.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

None

Disqualifiers

None

Trial population

Subjects implanted with the shoulder replacement medical devices manufactured by FX Shoulder Solutions and distributed by FX Shoulder Solutions

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

  • FX Artificial Shoulder Prosthesis

    Device

    Humelock II Anatomic Shoulder System, Humelock II Reversible Shoulder System, Humelock Reverse Shoulder System, Humeris Shoulder System, Easytech Anatomical Shoulder System, FXV135 Mini Shoulder System, FXV135 Humelock Shoulder System

Treatment groups

600 Participants
are divided into 1 treatment group
Group A: Subjects1 intervention

Trial outcomes

Primary outcomes

1

A patient is considered a success at post-operative follow-up based upon the following composite clinical success (CCS):

Adjusted Constant Score that is ≥ 54 and improvement of ≥ 10 points from baseline. No continuous radiolucency or device migration/subsidence No revision surgery No serious device related adverse event.

Time frame
2 years
2

Survivorship

Follow patient's post-operative to track survivorship.

Time frame
10 years

Secondary outcomes

1

Adjusted Constant Score

The Constant-Murley score (CMS) is a validated 100-points scale composed of a number of individual parameters. These parameters define the level of pain and the ability to carry out the normal daily activities of the patient. The test is divided into four subscales: pain (15 points), activities of daily living (20 points), strength (25 points) and range of motion (40 points) with the subject completing the assessment prior to the Investigator completing their part of the assessment. The higher the score, the higher the quality of the function. An Adjusted Constant score will be calculated using normalized values to account for age and gender, as based upon anatomical gender at birth.

Time frame
6 weeks, 3, 6, 12, and 24 months.
2

QuickDASH

QuickDASH measures an individual's ability to complete tasks, absorb forces, and severity of symptoms. The QuickDASH tool uses a 5-point Likert scale from which the patient can select an appropriate number corresponding to his/her severity level/ function level. The higher the score, the higher the function and lower pain in the patient.

Time frame
6 weeks, 3, 6, 12, and 24 months.
3

American Shoulder and Elbow Surgeon (ASES)

ASES is a validated patient-reported outcome which is composed of 10 functional questions and one pain VAS. The total score is of 100 maximum points and weighted evenly between pain and function

Time frame
6 weeks, 3, 6, 12, and 24 months
4

Visual Analog Scale (VAS).

A validated measurement of pain in a patient where 0 indicates no pain and 100 indicates severe pain. The VAS is a straight horizontal line of fixed length.

Time frame
6 weeks, 3, 6, 12, and 24 months

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.